Switching CGRP(r) MoAbs in migraine: what evidence?

William David Wells-Gatnik Paolo Martelletti

Published in: Expert opinion on biological therapy (2024)

While data considering the potential efficacy of CGRP(r) switching continues to grow, our expert opinion supports the most recent European Headache Federation statement regarding CGRP(r) MoAb prescribing practices, concluding that there remains insufficient data to determine the efficacy of this intervention. As this topic is of significant clinical importance, we recommend a call-to-action to expand on current data considering the therapeutic options for patients that discontinue CGRP(r) MoAb therapy.

Keyphrases

electronic health record
primary care
end stage renal disease
big data
newly diagnosed
chronic kidney disease
healthcare
prognostic factors
stem cells
patient reported outcomes
climate change
adverse drug
drug induced